Search

Your search keyword '"Communicable diseases -- Drug therapy"' showing total 1,142 results
Start Over Descriptor "Communicable diseases -- Drug therapy"
1,142 results on '"Communicable diseases -- Drug therapy"'

1. Data on Infectious Diseases and Conditions Discussed by a Researcher at Johns Hopkins University School of Medicine (Infectious Diseases Society of America 2024 Guidance on the Treatment of Antimicrobial-Resistant Gram-Negative Infections)

Subjects
Medical research, Medicine, Experimental, Communicable diseases -- Drug therapy, Societies, Beta lactamases, Infection -- Drug therapy, Associations, institutions, etc., Physical fitness, Health, Johns Hopkins University. School of Medicine
Abstract

2024 SEP 21 (NewsRx) -- By a News Reporter-Staff News Editor at Obesity, Fitness & Wellness Week -- Investigators publish new report on infectious diseases and conditions. According to news [...]

Published
2024

2. Reports on Microorganism Research Findings from National Institute for Infectious Diseases Provide New Insights [The Drug Susceptibility of Non-Tuberculous Mycobacteria (NTM) in a Referral Hospital in Rome from 2018 to 2023]

Subjects
Medical research, Medicine, Experimental, Communicable diseases -- Drug therapy, Tuberculosis -- Drug therapy, Disease susceptibility -- Drug therapy, Physical fitness, Health
Abstract

2024 SEP 14 (NewsRx) -- By a News Reporter-Staff News Editor at Obesity, Fitness & Wellness Week -- Fresh data on microorganism research are presented in a new report. According [...]

Published
2024

3. Systematic Review and Meta-analysis of Deaths Attributable to Antimicrobial Resistance, Latin America

Author

Ciapponi, Agustin, Bardach, Ariel, Sandoval, Maria Macarena, Palermo, Maria Carolina, Navarro, Emiliano, Espinal, Carlos, and Quiros, Rodolfo

Subjects
Communicable diseases -- Drug therapy, Mortality -- Evaluation -- Argentina, Drug resistance in microorganisms -- Statistics, Secondary data analysis -- Management, Company business management, Health
Abstract

Antimicrobial resistance (AMR) is a growing public health problem that affects health, the economy, and human development (1). A 2016 review of AMR showed that drug-resistant infections will kill 10 [...]

Published
2023
Full Text
View/download PDF

5. New COVID-19 Research from University of Medicine and Pharmacy Described (Rheumatoid Arthritis and COVID-19 at the Intersection of Immunology and Infectious Diseases: A Related PRISMA Systematic Literature Review)

Subjects
Communicable diseases -- Drug therapy, Rheumatoid factor, Immunotherapy, Arthritis -- Drug therapy, Medical colleges, Pharmacy, Severe acute respiratory syndrome -- Drug therapy, Business, Health, Health care industry
Abstract

2024 NOV 10 (NewsRx) -- By a News Reporter-Staff News Editor at Medical Letter on the CDC & FDA -- Researchers detail new data in COVID-19. According to news reporting [...]

Published
2024

6. Data on Norovirus Discussed by a Researcher at Division of Infectious Diseases and HIV Medicine (Sacred journeys and pilgrimages: health risks associated with travels for religious purposes)

Subjects
HIV (Viruses) -- Drug therapy, Medical research, Medicine, Experimental, Pilgrims and pilgrimages, Communicable diseases -- Drug therapy, Travelers, Health
Abstract

2024 SEP 20 (NewsRx) -- By a News Reporter-Staff News Editor at Health & Medicine Week -- Investigators discuss new findings in norovirus. According to news originating from Cape Town, [...]

Published
2024

7. Multispecific Antibody Therapeutics Clinical Trials FDA Approved Multispecific Antibodies Market Size Insight

Subjects
Communicable diseases -- Drug therapy, Drug approval, Monoclonal antibodies, General interest, News, opinion and commentary
Abstract

Delhi: Multispecific antibody therapeutics are rapidly emerging as a transformative approach in the treatment of various diseases, particularly cancer, autoimmune disorders, and infectious diseases. Unlike traditional monoclonal antibodies that target [...]

Published
2024

8. Drug resistance taking toll on health

Subjects
Communicable diseases -- Drug therapy, Drug resistance in microorganisms -- Drug therapy, Public health, News, opinion and commentary
Abstract

Nairobi, Aug. 19 -- The challenge of anti-microbial resistance is already taking a toll on animal health and, consequently, food and nutrition security. Public health is not spared either; the [...]

Published
2024

9. US FDA Approves Expanded Age Indication for GSK’s AREXVY, the First Respiratory Syncytial Virus (RSV) Vaccine for Adults Aged 50-59 at Increased Risk

Subjects
United States. Food and Drug Administration, Communicable diseases -- Drug therapy, Respiratory tract diseases -- Drug therapy, Adults, Vaccines, News, opinion and commentary
Abstract

PHILADELPHIA--(BUSINESS WIRE)--Jun 7, 2024-- GSK plc (LSE/NYSE: GSK) today announced that the US Food and Drug Administration (FDA) has approved AREXVY (Respiratory Syncytial Virus (RSV) Vaccine, Adjuvanted) for the prevention [...]

Published
2024

11. School of Pharmacy and Medical Sciences Researchers Add New Study Findings to Research in Cancer (Advances in Bacterial Lysate Immunotherapy for Infectious Diseases and Cancer)

Subjects
Oncology, Experimental, Communicable diseases -- Drug therapy, BCG vaccines, BCG, Immunotherapy, Cancer -- Care and treatment -- Drug therapy -- Research, Pharmacy, Vaccines, Health
Abstract

2024 JUL 10 (NewsRx) -- By a News Reporter-Staff News Editor at Vaccine Weekly -- Current study results on cancer have been published. According to news reporting out of the [...]

Published
2024

12. GSK to become a founding partner of Fleming Initiative to fight antimicrobial resistance (AMR) | GSK

Subjects
Communicable diseases -- Drug therapy, Drug resistance in microorganisms -- Drug therapy, Methicillin -- Health aspects, Public health -- Health aspects, Business, Business, international
Abstract

M2 PRESSWIRE-May 16, 2024-: GSK to become a founding partner of Fleming Initiative to fight antimicrobial resistance (AMR) | GSK (C)1994-2024 M2 COMMUNICATIONS RDATE:15052024 *Company makes [pounds sterling]45m pledge to [...]

Published
2024

13. Approximately USD 10.8 Million Invested in New Drug Development for Malaria and NTDs in Partners Including Japanese Pharma Shionogi, Mitsubishi Tanabe, and Eisai and Europe-Based Institutions

Subjects
Shionogi & Company Ltd. -- Investments, Eisai Company Ltd. -- Investments, Mitsubishi Tanabe Pharma Corp. -- Investments, World health, Communicable diseases -- Drug therapy, Drugs, Malaria -- Drug therapy, Vaccines, Pharmaceutical industry -- Investments, Company investment, General interest, News, opinion and commentary
Abstract

TOKYO: Global Health Innovative Technology Fund (GHIT Fund) has issued the following press release: The Global Health Innovative Technology (GHIT) Fund announced today a total investment of approximately JPY 1.64 [...]

Published
2024

14. Approximately USD 10.8 Million Invested in New Drug Development for Malaria and NTDs in Partners Including Japanese Pharma Shionogi, Mitsubishi Tanabe, and Eisai and Europe-Based Institutions

Subjects
Mitsubishi Tanabe Pharma Corp. -- Investments, Communicable diseases -- Drug therapy, Drugs, Malaria -- Drug therapy, Vaccines, Pharmaceutical industry -- Investments, Company investment, Business, News, opinion and commentary
Abstract

TOKYO, May 8, 2024 /PRNewswire/ -- The Global Health Innovative Technology (GHIT) Fund announced today a total investment of approximately JPY 1.64 billion (USD 10.8 million[sup.1]) in four projects for [...]

Published
2024

15. BiomX to Present Data from Phase 1b/2a Study of BX004 for the Treatment of Cystic Fibrosis Patients with Chronic Pulmonary Infections at the 34th European Congress of Clinical Microbiology and Infectious Diseases (ECCMID 2024)

Subjects
Communicable diseases -- Drug therapy, Cystic fibrosis -- Drug therapy, Infection -- Drug therapy, Microbiology -- Health aspects, Banking, finance and accounting industries, Business
Abstract

CAMBRIDGE, Mass. and NESS ZIONA, Israel, April 23, 2024 (GLOBE NEWSWIRE) -- BiomX Inc. (NYSE American: PHGE) ('BiomX' or the 'Company'), a clinical-stage company advancing novel natural and engineered phage [...]

Published
2024

16. GITAM invests Rs. 45 crore to set up MURTI for advanced research & drug discovery in cancer & infectious diseases

Subjects
Oncology, Experimental, Communicable diseases -- Drug therapy, Drug discovery, Natural language interfaces -- Planning, Computational linguistics -- Planning, Language processing -- Planning, Cancer -- Research, Company business planning, Company business management, Pharmaceuticals and cosmetics industries
Abstract

Byline: Nandita Vijay Gandhi Institute of Technology and Management (GITAM), campus in Vishakhapatnam houses R&D lab for biotechnology and drug discovery which will help create start-up eco-system. The 'Multidisciplinary Unit [...]

Published
2023

17. Findings in Breast Cancer Reported from National Institute of Allergy and Infectious Diseases (NIAID) [A Therapeutic Vaccine Targeting Rat BORIS (CTCFL) for the Treatment of Rat Breast Cancer Tumors]

Subjects
United States. National Institutes of Health -- Reports, United States. National Institute of Allergy and Infectious Diseases -- Reports, Women -- Health aspects, Communicable diseases -- Drug therapy, Immunotherapy -- Reports, Cancer -- Care and treatment, Vaccines -- Reports, Breast cancer -- Drug therapy, Health, Women's issues/gender studies
Abstract

2023 APR 13 (NewsRx) -- By a News Reporter-Staff News Editor at Women's Health Weekly -- New research on breast cancer is the subject of a new report. According to [...]

Published
2023

18. NRx Pharmaceuticals, Inc. (Nasdaq: NRXP) Announces FDA Qualified Infectious Disease Product (QIDP) and Fast Track Designation of NRX-101 in Complicated Urinary Tract Infection and Pyelonephritis

Subjects
United States. Food and Drug Administration, Urinary tract infections -- Drug therapy, Tetracycline -- Health aspects, Communicable diseases -- Drug therapy, Pyelonephritis -- Drug therapy, Intellectual property -- Health aspects, Tetracyclines -- Health aspects, Intellectual property, General interest, News, opinion and commentary
Abstract

RADNOR, Pa: NRx Pharmaceuticals has issued the following news release: NRx Pharmaceuticals, Inc. (Nasdaq: NRXP) ('NRx Pharmaceuticals', the 'Company'), a clinical-stage biopharmaceutical company, today announced that it has received Qualified [...]

Published
2024

19. World Molecular Diagnostics Market Research Report 2023-2028 - Companion Diagnostics and Molecular Pharmacokinetics Revolutionizes Drug Therapies

Subjects
Bio-Rad Laboratories Inc. -- Market research, Communicable diseases -- Drug therapy, Marketing research, Instrument industry -- Market research, Marketing research, Business, News, opinion and commentary
Abstract

DUBLIN, Jan. 18, 2024 /PRNewswire/ -- The https://www.researchandmarkets.com/reports/5921182/the-world-market-molecular-diagnostics-12th?utm_source=CI&utm_medium=PressRelease&utm_code=6jd9xm&utm_campaign=1926293+-+World+Molecular+Diagnostics+Market+Research+Report+2023-2028+-+Companion+Diagnostics+and+Molecular+Pharmacokinetics+Revolutionizes+Drug+Therapies&utm_exec=chdomspi report has been added toResearchAndMarkets.com's offering. The World Market for Molecular Diagnostics report delves into global market and regional markets, exploring the [...]

Published
2024

20. Studies from Baylor University College of Medicine in the Area of Avian Influenza (Bird Flu) Described [Safety and Immunogenicity of a Delayed Heterologous Avian Influenza A(H7n9) Vaccine Boost Following Different Priming Regimens: a Randomized ...]

Subjects
United States. National Institutes of Health -- Safety and security measures, Avian influenza -- Drug therapy, Medical research -- Safety and security measures, Medicine, Experimental -- Safety and security measures, Communicable diseases -- Drug therapy, Influenza vaccines -- Safety and security measures, Medical colleges -- Safety and security measures, Health, University of Maryland, College Park -- Safety and security measures, Baylor College of Medicine -- Safety and security measures
Abstract

2024 APR 10 (NewsRx) -- By a News Reporter-Staff News Editor at Vaccine Weekly -- Current study results on Animal Diseases and Conditions - Avian Influenza (Bird Flu) have been [...]

Published
2024

21. Australian gardener becomes first person to survive deadly flesh-eating bacteria; Woman treated with antibiotics and hyperbaric oxygen therapy to survive infection by pathogen that causes blackleg disease in cattle and sheepGet our morning and afternoon news emails, free app or daily news podcast

Subjects
Podcasting -- Health aspects, Communicable diseases -- Drug therapy, Electronic mail systems -- Health aspects, Bacteria -- Health aspects, Antibiotics -- Health aspects, E-mail, News, opinion and commentary
Abstract

Byline: Natasha May An Australian woman has became the first documented person in the world to survive a pathogen that is usually the cause of the deadly 'blackleg' disease in [...]

Published
2023

22. National Institute of Allergy and Infectious Diseases (NIAID) Researcher Releases New Data on Crohn's Disease (Inhibition of LRRK2 Kinase Activity in the Treatment of Crohn's Disease)

Subjects
United States. National Institute of Allergy and Infectious Diseases, Communicable diseases -- Drug therapy, Medical research, Medicine, Experimental, Physical fitness, Health
Abstract

2023 JAN 21 (NewsRx) -- By a News Reporter-Staff News Editor at Obesity, Fitness & Wellness Week -- Investigators discuss new findings in Crohn's disease. According to news originating from [...]

Published
2023

23. Recent Findings from National Institute for Allergy and Infectious Diseases Has Provided New Information about Malaria (Genetic Mapping of Determinants In Drug Resistance, Virulence, Disease Susceptibility, and Interaction of Host-rodent ...)

Subjects
United States. National Institutes of Health, Communicable diseases -- Drug therapy, Medical research, Medicine, Experimental, Virulence (Microbiology), Genetic research, Malaria -- Drug therapy, Drug interactions, Plasmodium falciparum, Disease susceptibility -- Drug therapy, Physical fitness, Health
Abstract

2022 DEC 10 (NewsRx) -- By a News Reporter-Staff News Editor at Obesity, Fitness & Wellness Week -- Researchers detail new data in Mosquito-Borne Diseases - Malaria. According to news [...]

Published
2022

24. Global ATR Protein Inhibitors Market Set to Revolutionize Cancer Treatment and Expand into Neurodegenerative and Infectious Diseases

Subjects
Communicable diseases -- Drug therapy, Cancer -- Care and treatment, Market trend/market analysis, General interest, News, opinion and commentary
Abstract

DUBLIN: RESEARCH AND MARKETS has issued the following news release: The 'Global ATR Protein Inhibitors Clinical Trials & Market Opportunity Insight 2024' report has been added to ResearchAndMarkets.com's offering. A [...]

Published
2023

25. Global ATR Protein Inhibitors Market Set to Revolutionize Cancer Treatment and Expand into Neurodegenerative and Infectious Diseases

Subjects
Communicable diseases -- Drug therapy, Cancer -- Care and treatment, Market trend/market analysis, Business, Business, international
Abstract

M2 PRESSWIRE-November 8, 2023-: Global ATR Protein Inhibitors Market Set to Revolutionize Cancer Treatment and Expand into Neurodegenerative and Infectious Diseases (C)1994-2023 M2 COMMUNICATIONS RDATE:08112023 The 'Global ATR Protein Inhibitors [...]

Published
2023

26. Global ATR Protein Inhibitors Market Set to Revolutionize Cancer Treatment and Expand into Neurodegenerative and Infectious Diseases - ResearchAndMarkets.com

Subjects
Communicable diseases -- Drug therapy, Cancer -- Care and treatment, Market trend/market analysis, Business, Business, international
Abstract

DUBLIN -- The 'Global ATR Protein Inhibitors Clinical Trials & Market Opportunity Insight 2024' report has been added to ResearchAndMarkets.com's offering. A promising frontier in cancer pharmaceutical research, the inhibition [...]

Published
2023

27. Medicinal Products: Hepatitis Drug Program In Packages I-ii For The Infectious Disease And Liver Disease Observation Ward And Drug Program In Package Iii For The Dialysis Center In The Health Care Complex In Debica

Subjects
Communicable diseases -- Drug therapy, Hepatitis -- Drug therapy, Business, international
Abstract

Contract notice: medicinal products: hepatitis drug program in packages i-ii for the infectious disease and liver disease observation ward and drug program in package iii for the dialysis center in [...]

Published
2023

28. Antibiotics Market To Reach USD 71.5 Billion By 2032, Says DataHorizzon Research

Subjects
Tetracycline, Communicable diseases -- Drug therapy, Plant metabolites, Drug resistance in microorganisms -- Drug therapy, Tetracyclines, Banking, finance and accounting industries
Abstract

(GlobeNewswire) - According to DataHorizzon Research, the antibiotics market size was valued at USD 42.1 Billion in 2022 and is expected to have a market size of USD 71.5 Billion [...]

Published
2023

29. New discovery may 'unlock' the future of infectious disease and cancer treatment

Subjects
Oncology, Experimental, Communicable diseases -- Drug therapy, Cancer -- Research, Business, international, University of Birmingham
Abstract

London: University of Birmingham has issued the following news release: Researchers have identified a 'guard mechanism' for a protein which attacks microbes in infected cells, opening the possibility of new [...]

Published
2023

30. MicuRx receives FDA Qualified Infectious Disease Product (QIDP) and Fast Track Designation for Contezolid and Contezolid acefosamil

Subjects
United States. Food and Drug Administration, Communicable diseases -- Drug therapy, Diabetic foot -- Drug therapy, Infection -- Drug therapy, Methicillin, Antibiotics, General interest, News, opinion and commentary
Abstract

FOSTER CITY: MicuRx Pharmaceuticals has issued the following news release: MicuRx Pharmaceuticals, Inc., a biopharmaceutical company focused on the discovery and development of novel anti-infective therapies for treating life-threatening infections, [...]

Published
2023

31. MicuRx receives FDA Qualified Infectious Disease Product (QIDP) and Fast Track Designation for Contezolid and Contezolid acefosamil

Subjects
United States. Food and Drug Administration, Communicable diseases -- Drug therapy, Diabetic foot -- Drug therapy, Infection -- Drug therapy, Methicillin -- Health aspects, Antibiotics -- Health aspects, Business, News, opinion and commentary
Abstract

FOSTER CITY, Calif., Sept. 22, 2023 /PRNewswire/ -- MicuRx Pharmaceuticals, Inc., a biopharmaceutical company focused on the discovery and development of novel anti-infective therapies for treating life-threatening infections, today announced [...]

Published
2023

32. New Bacillus Calmette-Guerin Vaccines Study Findings Recently Were Published by Researchers at National Institute for Communicable Disease Control and Prevention (Comparison of the Immunogenicity and Efficacy of rBCG-EPCP009, BCG Prime-EPCP009 ...)

Subjects
Medical research -- Comparative analysis, Medicine, Experimental -- Comparative analysis, Communicable diseases -- Drug therapy, BCG vaccines -- Comparative analysis, BCG -- Comparative analysis, Tuberculosis vaccines -- Comparative analysis, Infants -- Comparative analysis, Tuberculosis -- Drug therapy, Health
Abstract

2024 JAN 10 (NewsRx) -- By a News Reporter-Staff News Editor at Vaccine Weekly -- Research findings on bacillus Calmette-Guerin vaccines are discussed in a new report. According to news [...]

Published
2024

33. National Institute of Allergy and Infectious Diseases (NIAID) Researchers Highlight Recent Research in Malaria (Can incorporating genotyping data into efficacy estimators improve efficiency of early phase malaria vaccine trials?)

Subjects
United States. National Institute of Allergy and Infectious Diseases, Vaccination, Medical research, Medicine, Experimental, Communicable diseases -- Drug therapy, Malaria vaccine -- Product development, Malaria -- Drug therapy, Clinical trials, Vaccines -- Product development, Health
Abstract

2024 JAN 10 (NewsRx) -- By a News Reporter-Staff News Editor at Vaccine Weekly -- Research findings on malaria are discussed in a new report. According to news reporting out [...]

Published
2024

34. Researcher at University of Florence Zeroes in on Tuberculosis (Extrapulmonary and Drug-Resistant Childhood Tuberculosis: Unveiling the Disease to Adopt the Optimal Treatment Strategy)

Subjects
Communicable diseases -- Drug therapy, Antitubercular agents, Drug resistance in microorganisms -- Drug therapy, Drugs, Tuberculosis -- Drug therapy, Disease transmission, Health
Abstract

2024 JAN 2 (NewsRx) -- By a News Reporter-Staff News Editor at TB & Outbreaks Week -- New research on tuberculosis is the subject of a new report. According to [...]

Published
2024

35. The repertoire of maternal anti-viral antibodies in human newborns

Author

Pou, Christian, Nkulikiyimfura, Dieudonné, Henckel, Ewa, Olin, Axel, Lakshmikanth, Tadepally, Mikes, Jaromir, and Wang, Jun

Subjects
Antiviral agents -- Usage, Newborn infants -- Health aspects, Child health -- Analysis, Communicable diseases -- Drug therapy, Vaccines, Disease susceptibility, Immunoglobulins, Antibodies, Medical research, Immunoglobulin G, Antigenic determinants, Biological sciences, Health
Abstract

All circulating immunoglobulin G (IgG) antibodies in human newborns are of maternal origin.sup.1 and transferred across the placenta to provide passive immunity until newborn IgG production takes over 15 weeks after birth.sup.2. However, maternal IgG can also negatively interfere with newborn vaccine responses.sup.3. The concentration of IgG increases sharply during the third trimester of gestation and children delivered extremely preterm are believed to largely lack this passive immunity.sup.1,2,4. Antibodies to individual viruses have been reported.sup.5-12, but the global repertoire of maternal IgG, its variation in children, and the epitopes targeted are poorly understood. Here, we assess antibodies against 93,904 epitopes from 206 viruses in 32 preterm and 46 term mother-child dyads. We find that extremely preterm children receive comparable repertoires of IgG as term children, albeit at lower absolute concentrations and consequent shorter half-life. Neutralization of the clinically important respiratory syncytial virus (RS-virus) was also comparable until three months of age. These findings have implications for understanding infectious disease susceptibility, vaccine development, and vaccine scheduling in newborn children. A longitudinal survey of maternal antiviral antibodies in newborns provides a blueprint for understanding infectious disease susceptibility and vaccine development, and inform vaccine scheduling in newborn children., Author(s): Christian Pou [sup.1] , Dieudonné Nkulikiyimfura [sup.1] , Ewa Henckel [sup.2] [sup.3] , Axel Olin [sup.1] , Tadepally Lakshmikanth [sup.1] , Jaromir Mikes [sup.1] , Jun Wang [sup.1] , [...]

Published
2019
Full Text
View/download PDF

36. Findings from Jiamusi University Update Knowledge of Antiinfectives (Assembly of Two Pharmaceutical Salts of Sparfloxacin With Pyrocatechuic Acid: Enhancing In Vitro Antibacterial Activity of Sparfloxacin By Improving the Solubility and ...)

Subjects
Drugs -- Structure-activity relationships, Communicable diseases -- Drug therapy, Structure-activity relationship (Pharmacology) -- Testing, Sparfloxacin -- Patient outcomes, Health
Abstract

2022 JUL 30 (NewsRx) -- By a News Reporter-Staff News Editor at Obesity, Fitness & Wellness Week -- Investigators discuss new findings in Drugs and Therapies - Antiinfectives. According to [...]

Published
2022

37. Strengthening Capabilities in Nuclear Medicine, Radiation Oncology, and Radiopharmaceutical Production for Diagnostics and Treatment of Cancer and Non-Communicable Diseases (ARASIA)

Subjects
Nuclear energy, Communicable diseases -- Drug therapy, Radiation, Cancer -- Care and treatment, Business, international, International Atomic Energy Agency
Abstract

DURATION Four years BENEFICIARY COUNTRIES Member States from Asia and the Pacific. EXPECTED OUTCOME Cancer diagnostics and treatment methods and protocols of cancer and NCDs improved in ARASIA State Parties. [...]

Published
2023

38. Supply Of Medicines For The Treatment Of Infectious Diseases

Subjects
Communicable diseases -- Drug therapy, Business, international
Abstract

Tenders are invited for supply of medicines for the treatment of infectious diseases Major organization : STATE AUTONOMOUS HEALTH INSTITUTION OF THE PERM REGION 'CITY CLINICAL HOSPITAL 4' Address : [...]

Published
2023

39. Data from National Institute of Allergy and Infectious Diseases (NIAID) Provide New Insights into Lupus Nephritis (Successful Treatment of Paecilomyces Variotii Pneumonia and Lupus Nephritis With Posaconazole-cyclophosphamide Co-administration ...)

Subjects
United States. National Institutes of Health, United States. National Institute of Allergy and Infectious Diseases, Communicable diseases -- Drug therapy, Bacterial pneumonia -- Drug therapy, Cyclophosphamide, Lupus -- Drug therapy, Systemic lupus erythematosus -- Drug therapy, Pneumonia -- Drug therapy, Posaconazole, Health
Abstract

2023 SEP 18 (NewsRx) -- By a News Reporter-Staff News Editor at Respiratory Therapeutics Week -- Investigators publish new report on Kidney Diseases and Conditions - Lupus Nephritis. According to [...]

Published
2023

40. Antibody drugs could target infectious diseases - if costs come down

Author

Johnson, Carolyn Y.

Subjects
Communicable diseases -- Drug therapy, Monoclonal antibodies -- Prices and rates -- Usage, Company pricing policy, General interest, News, opinion and commentary
Abstract

Byline: Carolyn Y. Johnson At a malaria research conference five years ago in Senegal, scientist Timothy Wells presented an overview of medicines on the horizon, ending with a few slides [...]

Published
2023

41. Data from Weill Cornell Medicine Provide New Insights into Neutropenia (Colonization With Fluoroquinolone-resistant Enterobacterales Decreases the Effectiveness of Fluoroquinolone Prophylaxis In Hematopoietic Cell Transplant Recipients)

Subjects
United States. National Institute of Allergy and Infectious Diseases, Communicable diseases -- Drug therapy, Medical research, Medicine, Experimental, Neutropenia -- Drug therapy, Drug resistance in microorganisms -- Drug therapy, Levofloxacin, Hematopoietic stem cells -- Transplantation, Chemotherapy, Cancer -- Chemotherapy, Physical fitness, Health
Abstract

2022 JAN 22 (NewsRx) -- By a News Reporter-Staff News Editor at Obesity, Fitness & Wellness Week -- A new study on Leukocyte Diseases and Conditions - Neutropenia is now [...]

Published
2022

42. Japan - Eisai's Initiatives for Developing New Medicines for Neglected Tropical Diseases and Malaria and Commitment for Funding to the 3rd Phase of Global Health Innovative Technology Fund Activities

Subjects
Eisai Company Ltd. -- Product development, World health, Communicable diseases -- Drug therapy, Public-private sector cooperation, Drugs -- Product development, Developing countries, Malaria -- Drug therapy, Pharmaceutical industry -- Product development, General interest, World Health Organization
Abstract

India, May 27 -- Eisai Co., Ltd. has announced that it will grant a total of 625 million yen to the Global Health Innovative Technology Fund ('GHIT Fund') to fund [...]

Published
2023

43. Eisai's Initiatives for Developing New Medicines for Neglected Tropical Diseases and Malaria and Commitment for Funding to the 3rd Phase of Global Health Innovative Technology Fund Activities

Subjects
Eisai Company Ltd. -- Product development, World health, Communicable diseases -- Drug therapy, Public-private sector cooperation, Drugs -- Product development, Developing countries, Malaria -- Drug therapy, Pharmaceutical industry -- Product development, Business, general, World Health Organization
Abstract

TOKYO, May 25, 2023 - (JCN Newswire) - Eisai Co., Ltd. has announced that it will grant a total of 625 million yen to the Global Health Innovative Technology Fund [...]

Published
2023

44. INOVIO ANNOUNCES ORPHAN DRUG DESIGNATION FOR INO-3107 FOR THE TREATMENT OF RECURRENT RESPIRATORY PAPILLOMATOSIS FROM THE EUROPEAN COMMISSION

Subjects
United States. Food and Drug Administration, Communicable diseases -- Drug therapy, T cells, Orphan drugs, Papillomavirus infections -- Drug therapy, News, opinion and commentary, European Union, European Union. European Commission
Abstract

PLYMOUTH MEETING, Pa -- The following information was released by INOVIO: INOVIO (NASDAQ:INO), a biotechnology company focused on developing and commercializing DNA medicines to help treat and protect people from [...]

Published
2023

45. ZyVersa Therapeutics Adds Dr. Douglas Golenbock to Its Inflammatory Disease Scientific Advisory Board to Support Advancement of Inflammasome ASC Inhibitor IC 100

Subjects
Communicable diseases -- Drug therapy, Medical colleges, Immunoglobulin G, Monoclonal antibodies, Banking, finance and accounting industries, Business
Abstract

Dr. Golenbock is The Neil and Margery Blacklow Chair in Infectious Diseases and Immunology and Professor and Chief, Division of Infectious Diseases and Immunology at the UMass Chan Medical School [...]

Published
2023

46. A Total of Approximately 400 Million Yen Investment in Eisai, Ehime University, DNDi and Others for New Drug and Vaccine Development for Neglected Tropical Diseases

Subjects
Eisai Company Ltd. -- Investments, Communicable diseases -- Drug therapy, Malaria vaccine, Drugs, Malaria -- Drug therapy, Public health, Vaccines, Industrial research -- Japan, Pharmaceutical industry -- Investments, International agencies, Research and development, Company investment, Business, News, opinion and commentary
Abstract

TOKYO, March 30, 2023 /PRNewswire/ -- The Global Health Innovative Technology (GHIT) Fund announced today an investment totaling approximately 400 million yen (US$2.9 million[sup.1]) for the research and development of [...]

Published
2023

47. New Pharmacology Study Findings Recently Were Reported by Researchers at University of Nigeria (Zanthoxylum Species: A Review of Traditional Uses, Phytochemistry and Pharmacology in Relation to Cancer, Infectious Diseases and Sickle Cell Anemia)

Subjects
Sickle cell anemia -- Drug therapy, Communicable diseases -- Drug therapy, Pharmacology, Phytochemistry, Cancer -- Drug therapy, Physical fitness, Health, University of Nigeria
Abstract

2021 OCT 2 (NewsRx) -- By a News Reporter-Staff News Editor at Obesity, Fitness & Wellness Week -- Current study results on pharmacology have been published. According to news reporting [...]

Published
2021

48. US FDA approves AbbVie's Dalvance to treat ABSSSI in pediatric patients

Subjects
United States. Food and Drug Administration, Communicable diseases -- Drug therapy, Pediatrics, Staphylococcus aureus, Oxacillin, Staphylococcus aureus infections -- Drug therapy, Infection -- Drug therapy, Methicillin, Children -- Health aspects, Dalbavancin, Pharmaceuticals and cosmetics industries
Abstract

AbbVie announced that the US Food and Drug Administration (FDA) approved Dalvance (dalbavancin) for the treatment of acute bacterial skin and skin structure infections (ABSSSI) in pediatric patients from birth. [...]

Published
2021

49. Study Findings from National Institute of Communicable Diseases Broaden Understanding of Tuberculosis (Distribution and Clonality of drug-resistant tuberculosis in South Africa)

Subjects
Communicable diseases -- Drug therapy, Medical research, Medicine, Experimental, Drug resistance in microorganisms -- Drug therapy, Rifampin, Tuberculosis -- Drug therapy, Drug wholesalers, Physical fitness, Health
Abstract

2021 JUN 19 (NewsRx) -- By a News Reporter-Staff News Editor at Obesity, Fitness & Wellness Week -- Investigators discuss new findings in tuberculosis. According to news reporting from the [...]

Published
2021

50. PDS Biotech Announces Publication of Preclinical Infectimune,ao Based Vaccine Studies Demonstrating Effective Protection Against Viral Infection in Peer-Reviewed Journal, Viruses

Subjects
Communicable diseases -- Drug therapy, Medical research -- Forecasts and trends -- Health aspects, Medicine, Experimental -- Forecasts and trends -- Health aspects, T cells -- Forecasts and trends -- Health aspects, Biotechnology -- Health aspects -- Forecasts and trends, Influenza vaccines -- Health aspects -- Forecasts and trends, Biotechnology industry -- Forecasts and trends, Immunotherapy -- Forecasts and trends -- Health aspects, Recombinant proteins -- Forecasts and trends -- Health aspects, Market trend/market analysis, Business, international
Abstract

(GlobeNewswire) - PDS Biotechnology Corporation (Nasdaq: PDSB), a clinical-stage immunotherapy company developing a growing pipeline of targeted immunotherapies for cancer and infectious disease, announced that preclinical studies involving Infectimune, PDS [...]

Published
2023

Catalog

Books, media, physical & digital resources
See catalog results